Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diclofenac HPBCD
- Development stage
- Phase 3
- Lead developer
- IBSA
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous, Intramuscular, Intravenous
01
Overview
Diclofenac HPBCD is a novel injectable formulation of the nonsteroidal anti-inflammatory drug (NSAID) diclofenac complexed with hydroxypropyl-β-cyclodextrin (HPβCD). This formulation enhances the solubility and bioavailability of diclofenac for parenteral administration (subcutaneous, intramuscular, intravenous), enabling rapid onset of analgesic action at lower doses compared to conventional formulations. The mechanism of action is inhibition of cyclooxygenase enzymes (COX-1 and COX-2), leading to reduced synthesis of prostanoids involved in pain and inflammation. The addition of HPβCD allows for effective pain management with potentially improved tolerability and safety profile due to lower required doses. It is primarily indicated for acute pain conditions such as postoperative pain, musculoskeletal pain, back pain, inflammatory pain, and renal colic[2][5][8][9].
- Brand names
- AkisDicloin
- Other names
- diclofenac hydroxypropyl-β-cyclodextrinHPβCD-diclofenacdiclofenac/HPβCD
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on diclofenac HPBCD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diclofenac HPBCD.